
© 2024 LYNX-Werbemitteilung - Bitte beachten Sie den Haftungsausschluss
Realtime | Geld | Brief | Zeit |
---|---|---|---|
387,50 | 388,95 | 17:41 | |
387,55 | 388,95 | 17:41 |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
14:10 | Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek | ||
13:46 | Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold | ||
Di | Sodium channel blockers for pain: New opportunities after Vertex's 'watershed' moment | ||
Di | Vertex's new cystic fibrosis treatment approved in EU | ||
Di | Vertex Pharmaceuticals Incorporated: Vertex Announces European Commission Approval of ALYFTREK, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis | - ALYFTREK(deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR gene, making it the broadest label for... ► Artikel lesen |